Flagship Validated Antibodies
KO-Validated vs. KD-Validated: What Each Tier Actually Confirms
Not all antibody validation claims mean the same thing. Two terms — KO-validated and KD-validated — appear across antibody catalogs, including ours, but they describe different experimental evidence with different strengths and different blind spots. Knowing which tier backs a given antibody helps you judge how much weight to put on a reported band before you commit it to a multi-week experiment.
| Validation Dimension | KO-Validated Tier | KD-Validated Tier |
|---|---|---|
| Validation Method | Antibody is tested in a CRISPR/Cas9 gene-edited cell line in which the target gene has been fully disrupted, alongside a matched wild-type parental line run in parallel. | Antibody is tested in cells treated with targeted siRNA or shRNA against the gene of interest, compared against a non-targeting (scrambled) control under matched conditions. |
| What It Confirms | The detected band or signal is absent, or reduced to background, specifically in cells lacking the gene — demonstrating the antibody is not primarily reacting with an unrelated protein of similar size. | Signal intensity decreases in proportion to the degree of knockdown achieved, supporting that the detected signal tracks with the expression level of the intended target rather than a static background band. |
| Typical Evidence Generated | Paired western blot lanes (wild-type vs. knockout) and, where applicable, paired IHC or IF images showing loss of staining in the knockout cell line or tissue. | Western blot or IF comparison between knockdown and scrambled-control conditions, generally alongside a check of knockdown efficiency at the RNA or protein level. |
| Limitations | Confirms specificity in the cell type used for the knockout; does not guarantee identical performance across every tissue, species homolog or fixation protocol, and a complete knockout can occasionally be compensated by a paralogous protein. | Knockdown is typically partial rather than complete, so some residual signal is expected even in a successful experiment; off-target RNAi effects and variable knockdown efficiency can complicate interpretation relative to a full genetic knockout. |
Neither tier is strictly "better" in isolation — they answer slightly different questions. A KO-validated antibody gives you the cleanest possible negative control because the gene is physically removed, not just suppressed. A KD-validated antibody demonstrates a dose-responsive relationship between expression and signal, which is useful evidence when a full knockout line isn't available or viable for a given target. When comparing antibodies across the catalog, treat the validation tier as a data point about the strength of evidence behind the product, not a proxy for sensitivity, affinity or optimal dilution — those remain specific to each lot and assay.
Why Target Validation Matters for Reproducibility
Antibody-based detection methods — western blotting, immunohistochemistry, immunofluorescence, flow cytometry — rest on an assumption that is easy to overlook once an experiment becomes routine: that the antibody binds the protein it was raised against, and only that protein, under the conditions you're using it in. In practice, antibodies are rarely perfectly specific. A polyclonal antibody raised against a short immunizing peptide can recognize that same sequence, or a closely related one, in unrelated proteins. Paralogs, splice variants, post-translationally modified forms, and proteins that happen to share a short linear epitope can all produce a signal at a plausible molecular weight. The result is a band that looks correct, sits at the expected size on the blot, and passes a casual visual check — while actually reporting on something other than the intended target.
"A clean band on a western blot is not, by itself, evidence that an antibody is binding the protein you think it is."
This is not a hypothetical concern. Antibody specificity has repeatedly been identified as a significant contributor to irreproducible findings in cell and molecular biology, prompting journals, funding bodies and core facilities to push for stronger validation standards before a result built on antibody detection is accepted into a published figure. The practical risk is direct: a false-positive band can be mistaken for genuine target expression, a treatment or knockdown effect can appear larger or smaller than it really is because the antibody is partially detecting a different protein, and conclusions built on that signal can fail to replicate in another lab using a nominally identical antibody under slightly different conditions.
Genetic controls address this problem directly instead of inferring specificity from band size or literature citation alone. In a knockout control, the gene encoding the target protein is removed at the DNA level using CRISPR/Cas9 editing, so the protein cannot be synthesized by the cell under any condition. If the antibody is truly specific, the signal in the knockout line should disappear or drop to background; if a band remains, that band could not be the real target, however convincing it otherwise looked on its own. A knockdown control follows the same logic at the RNA level, using siRNA or shRNA to reduce — rather than eliminate — expression of the target transcript. Because knockdown is typically partial, a specific antibody should show a corresponding partial reduction in signal rather than a complete or absent change.
Running these controls before a product is listed does not change how an antibody performs; it changes what you know about it before you commit bench time to it. It establishes, in a documented and repeatable way, that the signal has been shown to depend on the presence of the target gene rather than on an off-target protein that happens to share an epitope. For a closer look at how this process is structured and documented across our catalog, see the methodology section of our About page.
New Validated Antibody Releases Newsletter
We add newly KO- and KD-validated antibodies to the catalog on a rolling basis, organized by pathway and validation tier. Subscribe to hear about new releases in your research area before they're broadly announced.